{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T01:49:08Z","timestamp":1780969748992,"version":"3.54.1"},"reference-count":36,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T00:00:00Z","timestamp":1736640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lecanemab, a novel monoclonal antibody targeting amyloid-\u03b2, has shown promise in treating Alzheimer's disease. Comprehensive post-marketing safety data analysis is crucial to understand its real-world risk profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the safety profile of lecanemab using data from the FDA Adverse Event Reporting System (FAERS), with a focus on nervous system disorders and amyloid-related imaging abnormalities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a disproportionality analysis using the FAERS database to evaluate the safety signals associated with lecanemab. Reporting odds ratio (ROR), proportional reporting ratio, empirical Bayesian geometric mean, and information component were calculated at both system organ class (SOC) and preferred term (PT) levels. Additionally, we performed a time-to-onset analysis using Weibull shape parameter estimation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Analysis at the SOC level revealed significant signals for nervous system disorders (ROR: 7.32, 95% CI: 6.69\u20138.00). At the PT level, strong signals were observed for amyloid-related imaging abnormalities, particularly those associated with microhemorrhages and oedema (ROR: 4122.81 and 3922.78, respectively). Headache was the most frequently reported adverse event (200 cases), followed by chills (107 cases) and fatigue (97 cases). Time-to-onset analysis showed a median time of 33 days (range: 1\u20131283) for all adverse events, with neurological events occurring slightly later (median: 42 days, range: 1\u20131260).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings highlight a distinct safety profile for lecanemab, with a predominant impact on the nervous system and a notable association with imaging abnormalities. These results underscore the importance of vigilant monitoring and further research to optimize the risk-benefit profile of lecanemab in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13872877241307246","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T02:22:34Z","timestamp":1736734954000},"page":"844-855","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Unveiling the safety profile of lecanemab: A comprehensive analysis of adverse events using FDA adverse event reporting system data"],"prefix":"10.1177","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6708-4267","authenticated-orcid":false,"given":"Wukun","family":"Ge","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Ninghai First Hospital, Ninghai, Ningbo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyan","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Women and Children's Hospital of Ningbo University, Ningbo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyao","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Ninghai First Hospital, Ninghai, Ningbo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuainan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Ninghai First Hospital, Ninghai, Ningbo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3834-591X","authenticated-orcid":false,"given":"Peizhi","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Women and Children's Hospital of Ningbo University, Ningbo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,1,12]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13809"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31828726f5"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00338-8"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04687-y"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01481-0"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01851-2"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jama.2023.12548","article-title":"Alzheimer drug lecanemab gains traditional FDA approval","volume":"330","author":"Harris E","year":"2023","unstructured":"Harris E. Alzheimer drug lecanemab gains traditional FDA approval. JAMA 2023; 330: 495.","journal-title":"JAMA"},{"key":"e_1_3_4_10_2","unstructured":"Alzheimer Drug Lecanemab Gains Traditional FDA Approval - PubMed https:\/\/pubmed.ncbi.nlm.nih.gov\/37466999\/ (2024 accessed 27 September 2024)."},{"key":"e_1_3_4_11_2","unstructured":"Leqembi | European Medicines Agency (EMA) https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/leqembi (2024 accessed 27 September 2024)."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14108"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.01.015"},{"issue":"1283247","key":"e_1_3_4_14_2","article-title":"Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database","volume":"14","author":"Liu W","year":"2023","unstructured":"Liu W, Du Q, Guo Z, et al. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database. Front Pharmacol 2023; 14: 1283247.","journal-title":"Front Pharmacol"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-021-07157-3"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02799-9"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2014.10.038"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0281-2"},{"issue":"242579","key":"e_1_3_4_19_2","article-title":"Lecanemab and vascular-amyloid deposition in brains of people with down syndrome","author":"Liu L","year":"2024","unstructured":"Liu L, Saba A, Pascual JR, et al. Lecanemab and vascular-amyloid deposition in brains of people with down syndrome. JAMA Neurol 2024; e242579.","journal-title":"JAMA Neurol"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70015-7"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4161"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323"},{"issue":"80","key":"e_1_3_4_23_2","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson CJ","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther 2021; 13: 80.","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"e_1_3_4_24_2","first-page":"14","article-title":"\u2013a clinical study in Alzheimer\u2019s disease with a protofibril selective A\u03b2 antibody","volume":"2016","author":"Logovinsky V","unstructured":"Logovinsky V, Satlin A, Lai R, et al. Safety and tolerability of BAN2401\u2013a clinical study in Alzheimer\u2019s disease with a protofibril selective A\u03b2 antibody. Alzheimers Res Ther 2016; 8: 14.","journal-title":"Alzheimers Res Ther"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24501-0"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa155"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","unstructured":"Weller J Budson A. Current understanding of Alzheimer\u2019s disease diagnosis and treatment. F1000Res 2018; 7: F1000 Faculty Rev-1161.","DOI":"10.12688\/f1000research.14506.1"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280231218253"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2021.01.002"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpet.2020.06.004"},{"issue":"529","key":"e_1_3_4_31_2","article-title":"In vivo imaging with 18F-FDG- and 18F-florbetaben-PET\/MRI detects pathological changes in the brain of the commonly Used 5XFAD mouse model of Alzheimer\u2019s disease","volume":"7","author":"Franke TN","year":"2020","unstructured":"Franke TN, Irwin C, Bayer TA, et al. In vivo imaging with 18F-FDG- and 18F-florbetaben-PET\/MRI detects pathological changes in the brain of the commonly Used 5XFAD mouse model of Alzheimer\u2019s disease. Front Med (Lausanne) 2020; 7: 529.","journal-title":"Front Med (Lausanne"},{"issue":"835577","key":"e_1_3_4_32_2","article-title":"Impact of donepezil on brain glucose metabolism assessed using [18F]2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging in a mouse model of alzheimer\u2019s disease induced by intracerebroventricular injection of amyloid-beta peptide","volume":"16","author":"Hugon G","year":"2022","unstructured":"Hugon G, Goutal S, Sarazin M, et al. Impact of donepezil on brain glucose metabolism assessed using [18F]2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging in a mouse model of alzheimer\u2019s disease induced by intracerebroventricular injection of amyloid-beta peptide. Front Neurosci 2022; 16: 835577.","journal-title":"Front Neurosci"},{"key":"e_1_3_4_33_2","article-title":"What drugmakers did not tell volunteers in Alzheimer\u2019s trials","author":"Bogdanich W","unstructured":"Bogdanich W, Kessler C. What drugmakers did not tell volunteers in Alzheimer\u2019s trials. The New York Times, 23 October 2024, https:\/\/www.nytimes.com\/2024\/10\/23\/health\/alzheimers-drug-brain-bleeding.html (2024, accessed 27 October 2024).","journal-title":"The New York Times"},{"issue":"1169499","key":"e_1_3_4_34_2","article-title":"Safety and efficacy of lecanemab for Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized clinical trials","volume":"15","author":"Qiao Y","year":"2023","unstructured":"Qiao Y, Chi Y, Zhang Q, et al. Safety and efficacy of lecanemab for Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized clinical trials. Front Aging Neurosci 2023; 15: 1169499.","journal-title":"Front Aging Neurosci"},{"issue":"2410021","key":"e_1_3_4_35_2","article-title":"Consumption of olive oil and diet quality and risk of dementia-related death","volume":"7","author":"Tessier A-J","year":"2024","unstructured":"Tessier A-J, Cortese M, Yuan C, et al. Consumption of olive oil and diet quality and risk of dementia-related death. JAMA Netw Open 2024; 7: e2410021.","journal-title":"JAMA Netw Open"},{"issue":"1408135","key":"e_1_3_4_36_2","article-title":"A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Wang K","year":"2024","unstructured":"Wang K, Wang M, Li W, et al. A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system. Front Pharmacol 2024; 15: 1408135.","journal-title":"Front Pharmacol"},{"issue":"53","key":"e_1_3_4_37_2","article-title":"Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review","volume":"19","author":"Prada-Ramallal G","year":"2019","unstructured":"Prada-Ramallal G, Takkouche B, Figueiras A. Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review. BMC Med Res Methodol 2019; 19: 53.","journal-title":"BMC Med Res Methodol"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877241307246","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877241307246","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877241307246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:09:32Z","timestamp":1777370972000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877241307246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,12]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1177\/13872877241307246"],"URL":"https:\/\/doi.org\/10.1177\/13872877241307246","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,12]]}}}